Improving the drug development process by reducing the impact of adverse events: The case of cataracts considered

Smith, Andrew F., Klotz, Alexander and Wormstone, I. Michael ORCID: https://orcid.org/0000-0002-6423-7766 (2016) Improving the drug development process by reducing the impact of adverse events: The case of cataracts considered. Drug Discovery Today, 21 (3). pp. 510-516. ISSN 1359-6446

Preview

PDF (Smith et al Final) - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (147kB) | Preview

Abstract

Cataract was used as a model for the prevalence and economic impact of adverse events during the drug development process. Meta-analysis revealed a reported prevalence of cataract at 12.0% (1.0–43.3%), 3.8% (2.4–12.5%), 1.0% (0.0–8.1%), 1.7% (0.0–34.8%) and 3.8% (2.3–5.7%) of compounds in preclinical, Phase I, II, III and IV clinical trials, respectively. Utilising a human-based in vitro screening assay to predict cataractogenic potential in human could allow better selection of novel compounds at early-stage drug development. This could significantly reduce costs and ultimately increase the probability of a drug obtaining FDA approval for a clinical application.

Item Type:	Article
Faculty \ School:	Faculty of Science > School of Biological Sciences Faculty of Science > School of Natural Sciences
UEA Research Groups:	Faculty of Science > Research Groups > Cells and Tissues
Depositing User:	Pure Connector
Date Deposited:	22 Mar 2016 09:23
Last Modified:	19 Apr 2023 23:49
URI:	https://ueaeprints.uea.ac.uk/id/eprint/57740
DOI:	10.1016/j.drudis.2016.01.001

Downloads

Actions (login required)

View Item